沙库巴曲缬沙坦钠联合芪苈强心胶囊对射血分数减低型心力衰竭患者炎症因子水平的影响
Effects of Shakubaqu Valsartan Sodium combined with Qiliqiangxin Capsule on Inflammatory Factors in Patients with Reduced Ejection Fraction Heart Failure
孙兰1
作者信息
- 1. 淄博市博山区人民医院心血管内科,山东淄博 255200
- 折叠
摘要
目的 探讨沙库巴曲缬沙坦钠联合芪苈强心胶囊对射血分数减低型心力衰竭患者炎症因子水平的影响.方法 选取2020 年9 月至2022 年9 月淄博市博山区医院心血管内科收治的90 例射血分数减低型心力衰竭患者作为研究对象,采用随机数字表法分为对照组与观察组,各45 例.两组均给予常规抗心力衰竭治疗,同时对照组口服沙库巴曲缬沙坦钠,观察组在对照组基础上口服芪苈强心胶囊,比较两组的治疗效果.结果 与治疗前比较,治疗后两组 6MWT均延长,LVEF均升高,LVEDD 均缩小,且观察组均优于对照组,差异有统计学意义(P＜0.05);治疗后两组血浆醛固酮(ALD)、血管紧张素Ⅱ(AngⅡ)、去甲肾上腺素(NE)及血清肿瘤坏死因子-α(TNF-α)、N 末端脑钠肽前体(NT-proBNP)、C 反应蛋白(CRP)均降低,且观察组均低于对照组,差异有统计学意义(P＜0.05);观察组与对照组不良反应发生率4.44%(2/45)、11.11%(5/45)比较,差异无统计学意义(P＞0.05).结论 沙库巴曲缬沙坦钠联合芪苈强心胶囊治疗射血分数减低型心力衰竭患者能够改善心功能,抑制神经内分泌系统过度激活,降低炎症因子水平,提升安全性.
Abstract
Objective To explore the impact of Shakubaqu valsartan sodium combined with Qiliqiangxin capsule on inflammatory factors in patients with reduced ejection fraction heart failure.Methods A total of 90 patients with heart failure with reduced ejection fraction admitted to the cardiovascular Department of Boshan Hospital of Zibo City from September 2020 to September 2022 were selected as the study objects,and were divided into control group and observation group by random number table method,with 45 cases in each group.Both groups were given conventional anti-heart failure treatment,while the control group was given sacubactril valsartan sodium,the observation group was given Qiliqiangxin capsule on the basis of the control group,and the therapeutic effect of the two groups was compared.Results Compared with before treatment,6MWT was prolonged,LVEF was increased and LVEDD was decreased in both groups after treatment,and observation group was superior to control group,the difference was statistically significant(P＜0.05).After treatment,plasma aldosterone(ALD),angiotensin Ⅱ(AngⅡ),norepinephrine(NE)and serum tumor necrosis factor-α(TNF-α),N-terminal brain natriuretic peptide precursor(NT-proBNP)and C-reactive protein(CRP)were decreased in both groups,and observation group were lower than control group,the difference was statistically significant(P＜0.05).There was no significant difference in the incidence of adverse reactions between the observation group and the control group 4.44%(2/45)and 11.11%(5/45)respectively(P＞0.05).Conclusion In the treatment of patients with reduced ejection fraction heart failure,sacubatrol valsartan sodium combined with Qiliqiangxin capsule can improve heart function,inhibit the overactivation of neuroendocrine system,reduce the level of inflammatory factors and improve safety.
关键词
芪苈强心胶囊/沙库巴曲缬沙坦钠/射血分数减低/心力衰竭Key words
Qiliqiangxin capsule/Shakubartri valsartan/Reduced ejection fraction/Heart failure引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据